Recombinant anti-human EGFR antibody/IL-10 bispecific Fc fusion protein(Dingfu Biotarget)

重组抗人EGFR抗体/IL-10双特异Fc融合蛋白（丁孚靶点）

Report date: 2026/03/11 20:02:12

Base Information

Drug NameRecombinant anti-human EGFR antibody/IL-10 bispecific Fc fusion protein(Dingfu Biotarget)

Drug Alias Name基于西妥昔单抗的IL-10融合蛋白（丁孚靶点）CmAb-(IL10)2DF203DF-203

ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein

Mechanisms of ActionInterleukin-10 replacementsAnti-Epidermal growth factor receptor erbB1

TargetsEpidermal growth factor receptor erbB1Interleukin 10 receptor

Therapy Area/IndicationsSolid tumoursAscitesPleural Effusion, Malignant

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaPhase 2 Clinical

China Registration ClassClass 1 therapeutic biologic in China

Inactive CompaniesN/A

Active IndicationsSolid tumoursAscitesPleural Effusion, Malignant

Inactive IndicationsN/A

ATC CodeN/A